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Key Points
• Improvements in
splenomegaly and symptoms
in patients receiving ruxolitinib
occurred regardless of the
mutations that were present.
• Ruxolitinib relieved the negative
impact of prognostically
detrimental mutations in
myelofibrosis patients from the
COMFORT-II study.
The JAK1/JAK2 inhibitor ruxolitinib produced significant reductions in splenomegaly and
symptomaticburdenand improvedsurvival inpatientswithmyelofibrosis (MF), irrespective
of their JAK2mutation status, in 2 phase III studies against placebo (COMFORT-I) and best
available therapy (COMFORT-II). We performed a comprehensive mutation analysis to
evaluate the impact of 14 MF-associated mutations on clinical outcomes in 166 patients
included inCOMFORT-II.We found that responses in splenomegaly and symptoms, aswell
as the risk of developing ruxolitinib-associated anemia and thrombocytopenia, occurred at
similar frequencies across different mutation profiles. Ruxolitinib improved survival in-
dependent of mutation profile and reduced the risk of death in patients harboring a set of
prognostically detrimentalmutations (ASXL1, EZH2, SRSF2, IDH1/2) with anhazard ratio of
0.57 (95% confidence interval: 0.30-1.08) vs best available therapy. These data indicate
that clinical efficacy and survival improvement may occur across different molecular
subsets of patients with MF treated with ruxolitinib. (Blood. 2014;123(14):2157-2160)
Introduction
Myeloﬁbrosis (MF),1 either primary (PMF) or evolved from poly-
cythemia vera (PPV-MF) or essential thrombocythemia (PET-MF), is
characterized by reduced survival (OS) and disabling symptoms.2-4
Conventional treatment is ineffective; stem cell transplantation is
reserved for younger patients with dismal outcome,5 as those included
in intermediate-2 (projected survival, 4-5 years) or high-risk (2-2.5
years) category of IPSS or DIPPS-plus prognostic scores.6-8
Activatingmutations in JAK2,MPL, and calreticulin are found in
@60%, 8%, and 15% to 25% of PMF patients, respectively.9-12
Overactivated JAK/STAT signaling is a hallmark ofMF independent
of mutations.13 Additional mutations14 in genes affecting the epi-
genetic machinery (TET2, ASXL1, DNMT3A, IDH1, and 2)15,16 and
the spliceosome (SRSF2, SF3B1, U2AF)17 are found in 5% to 25%
and may have prognostic relevance. We reported that PMF patients
harboring mutation in any 1 of EZH2, ASXL1, IDH1/2, and SRSF2
constituted an IPSS- and DIPSS-plus score–independent “high mo-
lecular risk” (HMR) category associated with shorter OS and
greater risk of leukemia compared with patients lacking the above
mutations (“low molecular risk”; LMR).18
Treatment with ruxolitinib, a JAK1 and JAK2 inhibitor, was as-
sociated with rapid and durable reductions in splenomegaly and
improvement of disease-related symptoms in MF patients compared
with placebo (COMFORT-I study)19 or best available therapy (BAT;
COMFORT-II).20 A survival beneﬁt in ruxolitinib-treated patients
was also demonstrated.21,22 The aim of this study was to analyze the
impact of MF-associated mutations on clinical response, hemato-
logical toxicity, and survival in a subset of patients receiving
ruxolitinib in COMFORT-II.
Study design
InCOMFORT-II,MFpatientswere randomized to receive ruxolitinib (n5 146)
or BAT (n5 73). After institutional review board approval and informedwritten
consent, sampleswere available in 166cases (ruxolitinib, n5120;BAT, n546;
76% of total; details in supplemental Material, available on the BloodWeb site).
This study was conducted in accordance with the Declaration of Helsinki.
Mutations in 14 genes (JAK2,MPL,EZH2,ASXL1,TET2, IDH1, IDH2,CBL,
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SRSF2, SOCS1, SOCS2, SOCS3, SH2B3, KRAS) were genotyped in blood
DNA at study entry by deep sequencingwith Ion Torrent-PGMorRoche-454
platform (described in supplemental Material).
The following end points were retrospectively correlated with mutation
status: spleen response, symptomatic improvement, developmentof ruxolitinib-
induced anemia and thrombocytopenia, and survival. Deﬁnitions are provided
in supplementalMaterial.We did not include leukemia transformation, because
the low number of events (5 in ruxolitinib [3.4%] and 4 in BAT [5.5%] arm)
prevented statistical analysis. Relationships between clinical end points and
mutations were investigated via descriptive statistics. Survival estimates were
obtained with the Kaplan-Meier method; the hazard ratio (HR) was determined
using Cox proportional hazards model stratiﬁed by baseline IPSS category.
Treatment effect and prognostic value of mutations with regard to OS were
analyzed using multivariate Cox regression adjusted for IPSS category.
Results and discussion
At study entry, patients’ characteristics, according to treatment
randomization, were similar regarding MF subtype, hematologic
values, spleen volume, symptomatic patients, IPSS risk category,
Figure 1. The frequency and the pairwise cooccurrence of mutations in the entire study cohort (n5 166). (A) These are represented by a Circos diagram. Cooccurring
mutations are indicated in the clockwise direction; the length of the arc corresponds to the frequency of mutation in the first gene (color coded), and the width of the ribbon
corresponds to the frequency of patients who also had a mutation in the second gene. The individual mutated genes for each patients in the whole cohort are indicated in (B).
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and JAK2V617F mutation, and were comparable to the entire
COMFORT-II series (supplemental Table 1). Mutations frequency
was: JAK2V617F 75.5%; MPLW515 7.7%; ASXL1 32.5%; TET2
10.7%; EZH2 7.2%; CBL 4.4%; SRSF2 3.0%; SH2B3 1.3%; IDH1
0.7%; IDH2 0.0%; SOCS1 0.7%; SOCS2 0.7%; SOCS3 0.0%;
KRAS 1.4% (Figure 1A). These frequencies were comparable in
ruxolitinib and BAT arms and were consistent with those previously
reported in 171 intermediate-2 and high-risk PMF subjects (supple-
mental Table 2).18 One hundred ﬁfty patients (90.4%) displayed at
least 1 mutation; 57 (34.3%), 5 (3.0%), and 5 (3.0%) patients had 2, 3,
and 4 mutations, respectively (Figure 1B). Overall, 46 (38.3%)
patients in ruxolitinib and 20 (43.5%) in BAT arm were classiﬁed
as HMR according to the presence of mutation(s) in any 1 of
ASXL1, EZH2, SRSF2, and IDH1-2.
In the set of 166 patients, a spleen responsewas achieved in 31.7%
and 35.0% of ruxolitinib arm respectively at 48 and 24 weeks vs 0%
and 0% in BAT. Symptomatic improvement, deﬁned from FACT-
Lym questionnaire for patients who were symptomatic at baseline
(ruxolitinib n5 82, BAT n5 20), was observed in 80.9% and 79.4%
in ruxolitinib armat 48 and24weeks comparedwith38.8%and 38.8%
in BAT. Anemia and thrombocytopenia developed respectively in
72.5% and 35.8% of ruxolitinib and 39.1% and 8.7% of BATpatients.
At themedian follow-up timeof 151weeks, themortality ratewas20%
(24of 120) in ruxolitinib and 34.8% (16of 46) inBATarm; themedian
survival was not reached in either. Patients in the ruxolitinib arm had
a survival advantage greater than BATwith a relative reduction of risk
of death by 47% (HR 0.53; 95% conﬁdence interval (CI), 0.28-0.99).
Overall, results in this patient subset were comparable to the entire
COMFORT-II series ruling out a selection bias eventually introduced
by the availability of DNA samples.
To ascertain correlations between outcomes and mutation pattern,
we compared HMR and LMR patients randomized to ruxolitinib. At
week 48, a.35% spleen volume reduction was achieved by 26.1% of
HMR and 35.0% of LMR patients; at week 24, corresponding ﬁgures
were 34.8% and 35.0%. The mean spleen volume reduction from
baseline at week 48 was 223.5% in HMR vs 230.6% in LMR,
and229.0% vs229.9% at week 24. No mutation was individually
considered correlated with spleen volume reduction. Constitutional
symptoms improved in 76.2% (16/21) of HMR vs 83.3% (35/42) of
LMR patients at week 48, and at week 24 the proportion was 85.7%
(18/21) in HMR vs 76.2% (32/42) in LMR. None of the previously
mentioned differences provided a statistically signiﬁcant result.
We then asked whether a HMR status eventually affected hema-
tologic toxicity associated with ruxolitinib. The percentage of patients
developing anemia was 74% and 72% in the HMR and LMR group.
Development of anemia was also unrelated to mutations in genes of
the JAK2/STAT signaling (JAK2, MPL, SH3B2, CBL, and SOCSs),
occurring in 72% of mutated anemic subjects vs 74% of wild type.
Ruxolitinib-associated thrombocytopenia occurred at similar rates in
HMR (34%) and LMR (36.5%) patients and independently of
mutations insisting on JAK2/STAT signaling (35.4% vs 39.1%
of wild-type patients).
With a median follow-up of 151 weeks, Kaplan-Meier estimates
of survival at 144weeks in patients treatedwith ruxolitinib were 0.79
for theHMRand 0.85 for theLMRcategory, comparedwith 0.58 and
0.71 inBATarm, therefore indicating a survival beneﬁt of ruxolitinib
treatment independent of molecular risk score (Figure 2) and con-
ﬁrming the negative signiﬁcance of HMR in the control popula-
tion.18 The survival beneﬁt was conﬁrmed in a multivariate Cox
model where the risk of death for HMR patients was reduced by 43%
(HR 5 0.57, 95% CI: 0.30-1.08) compared with BAT; also,
ruxolitinib-treated LMR patients had a reduction in risk compared
with HMR by 38% (HR 5 0.62, 95% CI: 0.33-1.16). It should be
noted, however, that the conﬁdence intervals for hazard ratios include
1, which is likely because of the sample size.
In conclusion, we conﬁrmed that previously described mutations
comprising a prognostically adverse HMR category in MF patients18
maintained their negative value in this subset of COMFORT-II
patients.16 The data presented showed that HMR status did not affect
the likelihood of obtaining a .35% spleen volume reduction or
symptomatic improvement, nor did it increase the risk of ruxolitinib-
associated anemia or thrombocytopenia. Additionally, our ﬁndings
indicated that ruxolitinib alleviated the negative prognostic impact
of mutations and overall suggest that clinical efﬁcacy and survival
improvement in MF patients may occur independently of the
underlying molecular pattern. There is no mechanistic explanation
yet on how these mutations affect survival in MF, and whether
ruxolitinib mitigated their signiﬁcance through anticlonal activity or
other mechanisms is the subject of ongoing investigations.
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